Linperlisib and chidamide

Phase 2Small molecule

YYanyan Liu

Linperlisib and chidamide is one of 5 small molecule programs targeting Chidamide. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChidamideRecruiting

ChidamidePhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Chidamide

#DrugCompanyPhaseTrials

Chidamide

CChipscreen Biosciences, Ltd.

Phase 3

7 2

Anti-CD19 CAR-T Cells

TThe Children's Hospital of Zhejiang University School of Medicine

Phase 2

1 3

Fludarabine and Cyclophosphamide

BBeijing Immunochina Medical Science & Technology Co., Ltd.

Phase 2

1 4

UB-421

UUnited BioPharma

Phase 2

1 5

Linperlisib and chidamide

YYanyan Liu

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Chidamide

NCT06421948

Clinical

Trials by Indication[1]

Chidamide1 trial

Linperlisib Combined With Chidamide in Patients With PTCL

Recruiting·YYanyan Liu·Phase 1/2·NCT06421948·134 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Linperlisib and chidamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Linperlisib and chidamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Linperlisib and chidamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yanyan Liu company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: YYanyan Liu

Linperlisib and chidamide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Chidamide1 trial

References

Drug Info

Quick Facts

Related News